SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

PRODUCT INFORMATION

Ticlopidine-d_4 (hydrochloride)

Item No. 33467

Formal Name: 5-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine, monohydrochloride-d_4, monohydrochloride
MF: $C_{14}H_{10}ClD_4NS \bullet HCl$
FW: 304.3
Chemical Purity: ≥98% (Ticlopidine)
Deuterium Incorporation: ≥99% deuterated forms (d_1-d_4); ≤1% d_0
Supplied as: A solid
Storage: -20°C
Stability: ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Ticlopidine-d_4 (hydrochloride) is intended for use as an internal standard for the quantification of ticlopidine (Item No. 20770) by GC- or LC-MS. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated *versus* unlabeled).

Ticlopidine-d_4 (hydrochloride) is supplied as a solid. A stock solution may be made by dissolving the ticlopidine-d_4 (hydrochloride) in the solvent of choice, which should be purged with an inert gas. Ticlopidine-d_4 (hydrochloride) is soluble in methanol and DMSO.

Description

Ticlopidine is a thienopyridine $P2Y_{12}$ receptor antagonist.[1] It inhibits aggregation of human platelets induced by collagen, arachidonic acid (Item No. 90010), and ADP (Item No. 16778; IC_{50}s = 75, 600, and 1,300 µM, respectively).[2] It also inhibits ADP-induced aggregation of rat platelets and decreases thrombus weight *in vivo* in a rat model of arterio-venous shunt thrombosis when administered at a dose of 100 mg/kg.[3] Ticlopidine (300 mg/kg) inhibits healing of acetic acid-induced gastric ulcers in rats.[4] Formulations containing ticlopidine have been used in the prevention of thrombotic stroke.

References

1. Porto, I., Giubilato, S., De Maria, G.L., *et al*. Platelet P2Y12 receptor inhibition by thienopyridines: Status and future. *Expert Opin. Investig. Drugs* **18(9)**, 1317-1332 (2009).
2. Bruno, J.J. The mechanisms of action of ticlopidine. *Thromb. Res. Suppl.* **4**, 59-67 (1983).
3. Sugidachi, A., Asai, F., Ogawa, T., *et al*. The *in vivo* pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties. *Br. J. Pharmacol.* **129(7)**, 1439-1446 (2000).
4. Ma, L., Elliott, S.N., Cirino, G., *et al*. Platelets modulate gastric ulcer healing: Role of endostatin and vascular endothelial growth factor release. *Proc. Nat. Acad. Sci. USA* **98(11)**, 6470-6475 (2001).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM